Browsing by Author "Horta, A."
Now showing 1 - 3 of 3
Results Per Page
Sort Options
- Glomerular filtration rate change during chronic hepatitis C treatment with Sofosbuvir/Ledipasvir in HCV/HIV Coinfected patients treated with Tenofovir and a boosted protease inhibitor: an observational prospective studyPublication . Soeiro, C.; Gonçalves, C.; Marques, M.; Méndez, M.; Tavares, A.; Horta, A.; Sarmento-Castro, R.INTRODUCTION: Concomitant use of ledipasvir and boosted protease inhibitors (PIs) may increase the risk of tenofovir (TDF) nephrotoxicity, since both these drugs increase TDF levels. Our aim was to evaluate glomerular filtration rate (eGFR) evolution during HCV treatment with sofosbuvir/ledipasvir (SOF/LDV) in HCV/HIV coinfected patients, according to their antiretroviral treatment (ARV). METHODS: Observational prospective study of HCV/HIV coinfected patients treated with SOF/LDV. eGFR evolution was evaluated during and 12 weeks after HCV treatment. Patients were categorized in three groups based on ARV regimen: non TDF, non-boosted TDF and TDF + boosted PI. RESULTS: We included 273 patients: 145 were receiving a non-TDF regimen, 78 a non-boosted TDF scheme and 50 were receiving TDF + boosted PI. We observed a statistically significant decrease in eGFR during treatment in all groups (non TDF p = 0.03, 95%CI [0.23-3.86], non-boosted TDF p < 0.01, 95%CI [3.36-7.44], TDF + PI p = 0.01, 95%CI [1.09-7.53]). The decrease was more pronounced in those receiving unboosted TDF (- 5.40 ml/min/1.73m2), but differences in eGFR decrease between the three groups were small and not statistically different (p = 0.06). eGFR decrease was greater in patients treated for 24 weeks (p = 0.009) and in cirrhotic patients (p = 0.036). At the end of follow up a recovery of eGFR was observed in all groups. CONCLUSION: We observed a significant decrease in eGFR during treatment in all study groups, that was small and reversible after SOF/LDV discontinuation. TDF was not associated with an increase in renal toxicity.
- Toxoplasmosis-associated IRIS involving the CNS: a case report with longitudinal analysis of T cell subsetsPublication . Rb-Silva, R.; Nobrega, C.; Reiriz, E.; Almeida, S.; Sarmento-Castro, R.; Correia-Neves, M.; Horta, A.BACKGROUND: HIV-infected patients may present an unforeseen clinical worsening after initiating antiretroviral therapy known as immune reconstitution inflammatory syndrome (IRIS). This syndrome is characterized by a heightened inflammatory response toward infectious or non-infectious triggers, and it may affect different organs. Diagnosis of IRIS involving the central nervous system (CNS-IRIS) is challenging due to heterogeneous manifestations, absence of biomarkers to identify this condition, risk of long-term sequelae and high mortality. Hence, a deeper knowledge of CNS-IRIS pathogenesis is needed. CASE PRESENTATION: A 37-year-old man was diagnosed with AIDS and cerebral toxoplasmosis. Anti-toxoplasma treatment was initiated immediately, followed by active antiretroviral therapy (HAART) 1 month later. At 2 months of HAART, he presented with progressive hyposensitivity of the right lower limb associated with brain and dorsal spinal cord lesions, compatible with paradoxical toxoplasmosis-associated CNS-IRIS, a condition with very few reported cases. A stereotactic biopsy was planned but was postponed based on its inherent risks. Patient showed clinical improvement with no requirement of corticosteroid therapy. Routine laboratorial analysis was complemented with longitudinal evaluation of blood T cell subsets at 0, 1, 2, 3 and 6 months upon HAART initiation. A control group composed by 9 HIV-infected patients from the same hospital but with no IRIS was analysed for comparison. The CNS-IRIS patient showed lower percentage of memory CD4+ T cells and higher percentage of activated CD4+ T cells at HAART initiation. The percentage of memory CD4+ T cells drastically increased at 1 month after HAART initiation and became higher in comparison to the control group until clinical recovery onset; the percentage of memory CD8+ T cells was consistently lower throughout follow-up. Interestingly, the percentage of regulatory T cells (Treg) on the CNS-IRIS patient reached a minimum around 1 month before symptoms onset. CONCLUSION: Although both stereotactic biopsies and steroid therapy might be of use in CNS-IRIS cases and should be considered for these patients, they might be unnecessary to achieve clinical improvement as shown in this case. Immunological characterization of more CNS-IRIS cases is essential to shed some light on the pathogenesis of this condition.
- Transmissão Mãe-Filho da Infeção pelo Vírus da Imunodeficiência Humana do tipo1Publication . Fernandes, A.; Amaral, B.; Carinhas, M.; Vasconcelos, O.; Horta, A.; Alexandrino, A.; Marques, L.Introdução: A Infeção pelo Vírus da Imunodeficiência Humana do tipo 1 (VIH1) na criança ocorre quase exclusivamente por transmissão mãe-filho (TMF). Sem profilaxia ocorrem taxas de transmissão de 15-25%, diminuindo para <2% quando são adotadas medidas adequadas. Objetivo: Avaliar a TMF da Infeção VIH numa maternidade. Material e Métodos: Estudo retrospetivo, com consulta do processo clínico, de crianças de mães com Infeção VIH1, nascidas na Maternidade Júlio Dinis de Janeiro de 2006 a Dezembro de 2011. Definida não Infeção se 2 testes virológicos negativos (um após os 4 meses) e ausência de clínica. Analise estatística – programa Epi-InfoR v.3.5.1 (Teste Fisher, p <0,05). Resultados: Nasceram 77 crianças com risco de transmissão VIH1, 45 do sexo masculino (58.4%) e 15 (19.5%) prematuros. Diagnostico de Infeção materna ocorreu na gestação em 24 (31.6%) e no parto numa (1.3%). Sete (9.2%) Não efetuaram terapêutica anti retrovirica (TARV) na gravidez e 9 (12.3%) apresentavam carga vírica >1.000 copias no parto. Nasceram por parto eutocico 4 (5.2%) e 10 (13%) tiveram rotura membranas (RM) ≥4h. Nenhum efetuou leite materno e todos fizeram profilaxia no periodo neonatal; 17 (22.1%) efetuaram profilaxia com 3 fármacos, associado a ausência de TARV na gravidez e parto, carga vírica materna >1.000 copias, RM≥4h, RM espontânea e prematuridade. Um recém-nascido (1.3%) faleceu. Nenhuma criança foi infetada. Cerca de um terço (35.5%) apresentou alterações hematológicas e 23 (30.3%) na função hepática, ambas reversíveis. Conclusão: Na população estudada não ocorreu TMF da Infeção VIH1, apesar de apresentar fatores que aumentam o risco de transmissão numa elevada percentagem de casos.